Aarti Drugs Book Value Per Share vs. Current Valuation
AARTIDRUGS | 453.80 9.05 2.03% |
For Aarti Drugs profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Aarti Drugs to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Aarti Drugs Limited utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Aarti Drugs's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Aarti Drugs Limited over time as well as its relative position and ranking within its peers.
Aarti |
Aarti Drugs Limited Current Valuation vs. Book Value Per Share Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Aarti Drugs's current stock value. Our valuation model uses many indicators to compare Aarti Drugs value to that of its competitors to determine the firm's financial worth. Aarti Drugs Limited is number one stock in book value per share category among its peers. It also is the top company in current valuation category among its peers reporting about 337,125,770 of Current Valuation per Book Value Per Share. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Aarti Drugs' earnings, one of the primary drivers of an investment's value.Aarti Current Valuation vs. Book Value Per Share
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Aarti Drugs |
| = | 139.96 X |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Aarti Drugs |
| = | 47.18 B |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Aarti Current Valuation vs Competition
Aarti Drugs Limited is the top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is presently estimated at about 64.32 Trillion. Aarti Drugs adds roughly 47.18 Billion in current valuation claiming only tiny portion of equities under Health Care industry.
Aarti Drugs Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Aarti Drugs, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Aarti Drugs will eventually generate negative long term returns. The profitability progress is the general direction of Aarti Drugs' change in net profit over the period of time. It can combine multiple indicators of Aarti Drugs, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last Reported | Projected for Next Year | ||
Accumulated Other Comprehensive Income | 343.7 M | 360.8 M | |
Operating Income | 2.8 B | 1.5 B | |
Income Before Tax | 2.4 B | 1.3 B | |
Total Other Income Expense Net | -421.8 M | -442.8 M | |
Net Income | 1.7 B | 1.3 B | |
Income Tax Expense | 639.4 M | 358.6 M | |
Net Income From Continuing Ops | 1.7 B | 1.4 B | |
Net Income Applicable To Common Shares | 1.9 B | 1.4 B | |
Interest Income | 299.6 M | 256.1 M | |
Net Interest Income | -335.2 M | -352 M | |
Change To Netincome | 297.2 M | 284.1 M |
Aarti Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Aarti Drugs. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Aarti Drugs position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Aarti Drugs' important profitability drivers and their relationship over time.
Use Aarti Drugs in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aarti Drugs position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aarti Drugs will appreciate offsetting losses from the drop in the long position's value.Aarti Drugs Pair Trading
Aarti Drugs Limited Pair Trading Analysis
The ability to find closely correlated positions to Aarti Drugs could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aarti Drugs when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aarti Drugs - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aarti Drugs Limited to buy it.
The correlation of Aarti Drugs is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aarti Drugs moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aarti Drugs Limited moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aarti Drugs can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Aarti Drugs position
In addition to having Aarti Drugs in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Cryptocurrency ETFs Thematic Idea Now
Cryptocurrency ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Cryptocurrency ETFs theme has 51 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cryptocurrency ETFs Theme or any other thematic opportunities.
View All Next | Launch |
Additional Tools for Aarti Stock Analysis
When running Aarti Drugs' price analysis, check to measure Aarti Drugs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aarti Drugs is operating at the current time. Most of Aarti Drugs' value examination focuses on studying past and present price action to predict the probability of Aarti Drugs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aarti Drugs' price. Additionally, you may evaluate how the addition of Aarti Drugs to your portfolios can decrease your overall portfolio volatility.